UNICREDIT BANK/CALL/BIOGEN IDEC/350/0.1/17.12.25 | Real-time BOERSE MUENCHEN 09:41:02 2024-07-11 am EDT | ||
| 1.49 EUR | +4.93% |
|
| Current month | -4.70% | ||
| 1 month | -6.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.49 | +4.93% |
| 24-07-10 | 1.42 | +5.97% |
| 24-07-09 | 1.34 | 0.00% |
| 24-07-08 | 1.34 | +3.88% |
| 24-07-05 | 1.29 | +2.38% |
Real-time BOERSE MUENCHEN
Last update July 11, 2024 at 09:41 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1US0 |
| ISIN | DE000HD1US07 |
| Date issued | 2024-01-15 |
| Strike | 350 $ |
| Maturity | 2025-12-17 (524 Days) |
| Parity | 10 : 1 |
| Emission price | 2.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.41 € |
|---|---|
| Lowest since issue | 0.68 € |
| Spread | 0.01 € |
| Spread % | 0.65% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
232.8
USD
Average target price
282
USD
Spread / Average Target
+21.17%
- Stock Market
- Warrants
- Warrant
